Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage
Autore:
Hop, JW; Rinkel, GJE; Algra, A; van der Sprenkel, JWB; van Gijn, J;
Indirizzi:
Univ Utrecht, Dept Neurol, NL-3508 GA Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA 3508 GA Utrecht, Netherlands Univ Utrecht, Dept Neurosurg, NL-3508 GA Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA 3508 GA Utrecht, Netherlands Univ Utrecht, Julius Ctr Patient Oriented Res, NL-3508 GA Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 GA 3508 GA Utrecht, Netherlands
Titolo Testata:
NEUROLOGY
fascicolo: 4, volume: 54, anno: 2000,
pagine: 872 - 878
SICI:
0028-3878(20000222)54:4<872:RPTOPA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEALTH SURVEY SF-36; CEREBRAL VASOSPASM; ANEURYSM-SURGERY; MANAGEMENT; QUALITY; TESTS;
Keywords:
subarachnoid hemorrhage; clinical trial; platelets; aspirin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Hop, JW Univ Utrecht, Dept Neurol, POB 85500, NL-3508 GA Utrecht, Netherlands Univ Utrecht POB 85500 Utrecht Netherlands NL-3508 GA Netherlands
Citazione:
J.W. Hop et al., "Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage", NEUROLOGY, 54(4), 2000, pp. 872-878

Abstract

Objective: To assess the safety and feasibility of a clinical trial on theeffectiveness of acetylsalicylic acid (ASA) in subarachnoid hemorrhage (SAH). Background: Several studies have indicated that increased platelet activity might be involved in the pathogenesis of delayed cerebral ischemia (DCI) after SAH. Method: Fifty patients who had early surgery (less than or equal to 4 days) for a ruptured aneurysm were enrolled in this randomized, double-blind, placebo-controlled trial. Trial medication, consisting of suppositories with 100 mg ASA versus placebo, was star ted immediately after surgical clipping of the aneurysm and continued for 21 days. End points were functional outcome and quality of life at 4 months, clinical deterioration after operation, development of DCI, hypodense lesion on postoperative CT, and hemorrhagic complications. Results: One-third of all patients with aneurysmal SAH were eligible for the trial. Fifteen of 26 patients receiving placebo deteriorated clinically versus 10 of 24 patients receiving ASA; 4 patients in each group deteriorated from DCI. Postoperative hypodensities on CTwere observed in 27 patients, distributed equally in both groups. Functional outcome and quality-of-life scores were slightly in favor of patients who had received ASA, but not to a significant degree (p = 0.22). Two patients in the ASA group had an a symptomatic hemorrhagic complication, and one patient in the placebo group had a fatal and another a symptomatic hemorrhagic complication. Conclusion: This pilot study shows that a clinical trial of acetylsalicylic acid (ASA) in subarachnoid hemorrhage (SAH) is feasible and probably safe. The effectiveness of ASA on functional outcome and delayed cerebral ischemia has to be studied in a larger trial.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 07:14:42